Key takeaways
Oral GLP-1 medications — including the Wegovy pill, Rybelsus, Ozempic pill, and Foundayo — can cause digestive side effects like nausea, diarrhea, vomiting, and stomach pain, similar to injectable versions.
These side effects are usually mild to moderate, tend to peak when you start treatment or increase your dose, and often improve as your body adjusts to the medication.
Serious but rare side effects include inflammation of the pancreas (pancreatitis), gallbladder disease, and severe allergic reactions.
Eating smaller meals, avoiding fatty foods, and taking your medication as directed can help reduce the severity of side effects.
Here's what we'll cover
Here's what we'll cover
Here's what we'll cover
Key takeaways
Oral GLP-1 medications — including the Wegovy pill, Rybelsus, Ozempic pill, and Foundayo — can cause digestive side effects like nausea, diarrhea, vomiting, and stomach pain, similar to injectable versions.
These side effects are usually mild to moderate, tend to peak when you start treatment or increase your dose, and often improve as your body adjusts to the medication.
Serious but rare side effects include inflammation of the pancreas (pancreatitis), gallbladder disease, and severe allergic reactions.
Eating smaller meals, avoiding fatty foods, and taking your medication as directed can help reduce the severity of side effects.
Glucagon-like peptide-1 (GLP-1) pills are a needle-free alternative to injectable GLP-1 receptor agonists. While they’re taken in different ways, both medications mimic a gut hormone to help control blood sugar and appetite.
There are currently four oral GLP-1 medications available in the United States: the Wegovy pill, Foundayo, Rybelsus*, and Ozempic pill.
Like all medications in this class, they do come with side effects. Here's what to know about GLP-1 pill side effects before you get started.
*As of May 2026, the brand name Rybelsus is being phased out and transitioning fully to the Ozempic pill. That said, inventory of original Rybelsus doses (3 mg, 7 mg, 14 mg) will remain available until depleted.
What are the most common side effects of GLP-1 pills?
The most common side effects of GLP-1 pills are digestive, and nausea is the one people report the most in clinical trials.
Gastrointestinal side effects, especially nausea, happen because GLP-1 receptor agonists slow gastric emptying, so food sits in your stomach longer than usual. That's part of what makes them effective for weight loss and blood sugar control. But it can also leave your stomach feeling uncomfortable, especially as you adjust to each dose.
How often these side effects show up varies by medication. In trials of the Wegovy pill, digestive symptoms such as nausea, vomiting, and constipation were the most commonly reported side effects.
For the Ozempic pill and Rybelsus, vomiting affected up to 10% of adults with type 2 diabetes, and diarrhea affected up to 15%. Most cases were mild to moderate.
Foundayo (orforglipron) has similar side effects, with digestive symptoms most commonly reported during the dose-escalation period of treatment.
People most commonly report:
Diarrhea
Vomiting
Stomach pain or cramping
Decreased appetite
Indigestion or acid reflux
Burping or bloating
Headache
Side effects tend to peak during dose increases and then settle as your body gets used to the medication.
How long do GLP-1 pill side effects last?
GLP-1 pill side effects are usually worse in the first few weeks of treatment and again after each dose increase. They then tend to ease as your body adjusts to the medication.
This pattern tracks with the dose-escalation schedule your provider follows when starting you on treatment.
Because doses are increased gradually, not all at once, side effects tend to come in waves instead of staying constant.
Do GLP-1 pills have fewer side effects than injections?
GLP-1 pills don't necessarily have fewer side effects than injectable versions. Both forms primarily cause digestive side effects because they operate through the same mechanism regardless of delivery method.
That said, there are a few differences worth knowing:
Oral semaglutide (Wegovy pill, Rybelsus, Ozempic pill) has strict dosing requirements. It must be taken on an empty stomach with no more than 4 oz of plain water, at least 30 minutes before eating, drinking, or taking other medications. Taking it incorrectly can reduce absorption and increase digestive discomfort.
Foundayois a bit more flexible, as it can be taken with or without food.
The Wegovy pill produces similar side effects to Foundayo and injectable Wegovy, with digestive symptoms as the most commonly reported adverse events.
Injectable versions of semaglutide bypass the digestive system at first, so your body tends to respond to them more predictably over time. That said, they can cause mild injection site reactions that pills don't.
With both pills and injections, how well you tolerate a GLP-1 usually depends on your dose and how gradually it’s increased.
Oral and injectable semaglutide differ in other ways too, from dosing to how they’re taken.
Serious but rare side effects of GLP-1 pills
Serious side effects of GLP-1 pills are uncommon, but knowing what to watch for is still important.
Pancreatitis
Inflammation of the pancreas (pancreatitis) has been reported with GLP-1 drugs.
Across oral semaglutide medications, it was recorded as a serious adverse event in about 0.1% of treated patients.
Symptoms include severe abdominal pain that may spread to the back, often worsening after eating.
People with a history of pancreatitis should discuss this risk with their healthcare provider before starting treatment. If you develop these symptoms, contact your healthcare provider right away.
Gallbladder disease
GLP-1 medications have beenassociated with an increased risk of gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis), particularly at higher doses.
If you experience sudden upper right abdominal pain, nausea, or fever, seek medical attention.
Thyroid tumors (theoretical risk)
Semaglutidecaused thyroid C-cell tumors in animal studies, though no cases of medullary thyroid carcinoma (MTC) have been confirmed in humans.
Semaglutide in pill form is not recommended for people with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Severe allergic reactions
Serious allergic reactions, including anaphylaxis and angioedema, have been reported with oral semaglutide.
Seek emergency care if you experience swelling of the face, lips, or throat, or difficulty breathing.
Dehydration and kidney problems
Severe digestive side effects can lead to dehydration and, in some cases, acute kidney injury.
People with reduced kidney function should be closely monitored when starting a GLP-1 medication. If you are unable to keep anything down, seek emergency medical attention. You might need IV fluids.
Low blood sugar (hypoglycemia)
On their own, GLP-1 pillsrarely cause low blood sugar. But the risk increases when they're combined with insulin or insulin secretagogues, such as sulfonylureas.
If you're already taking one of those medications for blood sugar control, tell your healthcare provider before you start a GLP-1 pill — they may want to adjust your insulin or sulfonylurea dose to lower your risk of low blood sugar. Don't stop or lower any of your doses on your own once you've started. If you experience low blood sugar, drink juice or eat another source of sugar right away, and make sure to tell your healthcare provider.
How to manage GLP-1 pill side effects
Most digestive side effects won't stick around forever, and there are a few things you can do to make them easier to handle:
Eat smaller, more frequent meals. Large meals make the stomach-slowing effect of GLP-1 medications more noticeable. Smaller portions spread across the daycan help reduce nausea and bloating.
Avoid high-fat and spicy foods. Fatty meals slow digestion even further, which can worsen nausea and indigestion early in treatment.
Take your medication correctly, as directed. Your prescription will come with specific instructions. For example, the Wegovy pill should be taken in the morning on an empty stomach with no more than 4 oz of water, swallowed whole. If you miss a dose, skip it, rather than doubling up.
Ask about a slower dose escalation. Side effects tend to flare up right after a dose increase, which is why your healthcare provider will only increase the dose once your body adjusts to the last one. Gradual increases are linked to better tolerability, so ask your provider about slowing down if it's too disruptive.
Stay hydrated. Vomiting and diarrhea can quickly cause dehydration, so sip fluids throughout the day — general guidance suggests roughly 11–16 cups of water daily, though how much you need on a GLP-1 varies. Skip sugary drinks in favor of low- or zero-calorie options, as added calories can work against weight loss goals and also raise blood sugar — something to watch more closely if you're managing type 2 diabetes.
Don't lie down right after eating. Staying upright and moving after meals, rather than lying down soon after eating, can potentially reduce acid reflux and heartburn symptoms.
Severe, persistent, or worsening side effects are worth discussing with your healthcare provider.
Don’t attempt to stop or lower your dose on your own, even if you’re struggling with side effects. Switching formulations or adjusting your dose is a conversation best had with a professional.
What are GLP-1 pills prescribed for?
The Wegovy pill, Rybelsus, Ozempic pill, and Foundayo are each intended for a different, sometimes overlapping, use:
Wegovy pill (oral semaglutide): Approved for chronic weight management and to reduce cardiovascular risk in adults with established heart disease and obesity or overweight. The injection form is also approved to treat a liver disease called MASH (noncirrhotic metabolic dysfunction-associated steatohepatitis).
Rybelsusa and Ozempic pill (oral semaglutide): Approved for type 2 diabetes and to reduce the risk of major cardiovascular events in adults with type 2 diabetes at increased cardiovascular risk. Sometimes prescribed off-label for weight loss.
Foundayo (orforglipron): Approved for weight loss.
Bottom line
GLP-1 pills can be effective for managing type 2 diabetes, weight loss, and cardiovascular risk, but like any medication, there are some side effects that are helpful to know about before you start.
Digestive symptoms are the most commonly reported side effects of oral GLP-1s. These include nausea, diarrhea, vomiting, and stomach discomfort. But they're generally mild and tend to improve over time.
GLP-1 pill side effects typically peak during dose increases. They ease as your body adjusts.
Different pills are approved for different uses. The Wegovy pill is approved for weight management and cardiovascular risk reduction, Rybelsus and the Ozempic pill are approved for type 2 diabetes and cardiovascular risk reduction, and Foundayo is approved for weight management.
Serious side effects of oral GLP-1s are uncommon. Pancreatitis, gallbladder disease, and severe allergic reactions are rare, but seek medical attention right away if you experience any severe or concerning symptoms.
There are ways to reduce the severity of side effects. Smaller meals, proper dosing technique, and gradual dose increases can all help combat nausea and other gastrointestinal side effects.
If you're thinking about starting a GLP-1 pill, Ro's healthcare providers can help you weigh your options and find the right fit.
Frequently asked questions (FAQs)
Do GLP-1 pill side effects last long?
No, GLP-1 pill side effects usually come and go rather than lasting continuously. They can flare up early on and again after each dose increase, then ease in between. Because oral GLP-1 doses usually step up after at least 30 days, that pattern can repeat at each increase until you reach your maintenance dose.
Side effects that persist or seriously disrupt daily life should be discussed with a healthcare provider.
What should I do if I have a serious side effect from a GLP-1 pill?
If you’re experiencing a serious side effect from a GLP-1 pill, contact your healthcare provider right away. Seek emergency care if you notice signs of a severe allergic reaction, such as swelling of the face, lips, or throat.
Other reasons to seek emergency medical attention are severe or sudden abdominal pain with nausea, vomiting, or even fever. If you can’t keep any fluids down, you should seek emergency medical care to avoid severe dehydration. These are only some of the reasons you should seek immediate medical care. If in doubt, always seek medical attention to be on the safer side.
Can GLP-1 pills cause cosmetic changes like "Ozempic face"?
Yes. While “Ozempic face” isn’t an official medical term, weight loss from GLP-1 medications, pills included, can lead to noticeable facial volume loss, sometimes called "Ozempic face." This isn't unique to any one drug; it reflects rapid fat loss rather than a specific side effect of the medication itself.
What happens after stopping GLP-1 pills?
After stopping a GLP-1 pill, appetite tends to return, and some weight regain is common within the following months. These medications work partly by curbing appetite, so hunger typically returns once the drug clears your system.
Any digestive side effects typically ease around the same time. Talk to your healthcare provider before stopping so you can plan for any changes.
DISCLAIMER
If you have any medical questions or concerns, please talk to your healthcare provider. The articles on Health Guide are underpinned by peer-reviewed research and information drawn from medical societies and governmental agencies. However, they are not a substitute for professional medical advice, diagnosis, or treatment.
GLP-1 Important Safety Information: Read more about serious warnings and safety info.
Wegovy Important Safety Information: Read more about serious warnings and safety info.
Foundayo Important Safety Information: Read more about serious warnings and safety info.
Ozempic Important Safety Information: Read more about serious warnings and safety info.
References
Daneshgaran, G., Shauly, O., & Gould, D. J. (2025). "Ozempic face" in plastic surgery: A systematic review of the literature on GLP-1 receptor agonist mediated weight loss and analysis of public perceptions. Aesthetic Surgery Journal Open Forum, 7, ojaf056. doi: 10.1093/asjof/ojaf056. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12232544/
Faizan, U. & Rouster, A. S. (2023). Nutrition and Hydration Requirements In Children and Adults. StatPearls. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK562207/
Filippatos, T. D., Panagiotopoulou, T. V., Elisaf, M. S. (2014). Adverse effects of GLP-1 receptor agonists. Review of Diabetic Studies, 11(3-4), 202–230. doi: 10.1900/RDS.2014.11.202. Retrieved from https://pubmed.ncbi.nlm.nih.gov/26177483/
Gunning, K. (2020). Oral semaglutide: Balancing promising therapeutics with adverse effects and access barriers. Journal of Managed Care & Specialty Pharmacy, 26(9), 1077–1079. doi: 10.18553/jmcp.2020.26.9.1077. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10391108/
Husain, M., Birkenfeld, A. L., Donsmark, M., et al. (2019). Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 381(9), 841–851. doi: 10.1056/NEJMoa1901118. Retrieved from https://pubmed.ncbi.nlm.nih.gov/31185157/
Karim, S., Jafri, W., Faryal, A., et al. (2011). Regular post dinner walk; can be a useful lifestyle modification for gastroesophageal reflux. Journal of the Pakistan Medical Association, 61(6), 526-30. Retrieved from https://pubmed.ncbi.nlm.nih.gov/22204202/
Kommu, S. & Whitfield, P. (2024). Semaglutide. StatPearls. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK603723/
Little, T.J., Horowitz, M., Feinle-Bisset, C. (2007). Modulation by high-fat diets of gastrointestinal function and hormones associated with the regulation of energy intake: implications for the pathophysiology of obesity. American Journal of Clinical Nutrition, 86(3), 531-41. doi: 10.109. Retrieved from https://pubmed.ncbi.nlm.nih.gov/17823414/
Novo Nordisk. (2026). Novo Nordisk's Ozempic® pill, the only FDA-approved oral peptide GLP-1 medication for adults with type 2 diabetes, soon to be available in the US. Novo Nordisk USA. Retrieved from https://www.novonordisk-us.com/media/news-archive/news-details.html?id=916540
U.S. Food and Drug Administration (FDA-a). (2026). Highlights of prescribing information: Foundayo (orforglipron) tablets, for oral use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf
U.S. Food and Drug Administration (FDA-b). (2026). Highlights of prescribing information: Rybelsus (semaglutide) tablets, for oral use; Ozempic (semaglutide) tablets, for oral use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213051s030lbl.pdf
U.S. Food and Drug Administration (FDA-c). (2026). Highlights of prescribing information: Wegovy (semaglutide) injection, for subcutaneous use; Wegovy (semaglutide) tablets, for oral use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218316s007lbl.pdf
West, S., Scragg, J., Aveyard, P., et al. (2026). Weight regain after cessation of medication for weight management: Systematic review and meta-analysis. BMJ (Clinical Research Ed.), 392, e085304. doi: 10.1136/bmj-2025-085304. Retrieved from https://pubmed.ncbi.nlm.nih.gov/41500720/
Wharton, S., Lingvay, I., Bogdanski, P., et al. (2025). Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. New England Journal of Medicine, 393(11), 1077–1087. doi: 10.1056/NEJMoa2500969. Retrieved from https://pubmed.ncbi.nlm.nih.gov/40934115/
Zhang, Y., Zhang, C., Gong, X., et al. (2026). Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: A systematic review and pairwise and network meta-analysis of randomized controlled trials. European Journal of Medical Research, 31(1), 318. doi: 10.1186/s40001-026-03933-9. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12918571/
Zinman, B., Aroda, V. R., Buse, J. B., et al. (2019). Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: The PIONEER 8 trial. Diabetes Care, 42(12), 2262–2271. doi: 10.2337/dc19-0898. Retrieved from https://pubmed.ncbi.nlm.nih.gov/31530667/














